Myriad Genetics has submitted a supplementary premarket approval application to FDA for its BRACAnalysis CDx test as a companion diagnostic to AstraZeneca’s and Merck’s PARP inhibitor Lynparza for men with metastatic castration-resistant prostate cancer.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe